SCHEMBL21940484

SCHEMBL21940484

COc1cc(C#N)nnc1-c1cn(C)nc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ S1PR2 O95136 10/20 0.42
▸ CYP3A4 P08684 1/20 0.39
▸ TTK P33981 1/20 0.38
▸ FGFR1 P11362 1/20 0.37
▸ FGFR2 P21802 1/20 0.37
▸ FGFR3 P22607 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ NR3C1 P04150 2/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ PGR P06401 1/20 0.33
▸ WDR5 P61964 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20606887 0.84 S1PR2 (0.50) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL21940579 0.81 S1PR2 (0.40) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL20606814 0.81 S1PR2 (0.42) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL20606795 0.79 S1PR2 (0.39) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL21941072 0.78 S1PR2 (0.41) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL21819827 0.78 S1PR2 (0.41) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL21940285 0.76 S1PR2 (0.40) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL21940576 0.75 KDM4E (0.39) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL21940479 0.72 CYP2C19 (0.41) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL21940475 0.71 S1PR2 (0.42) CYP2C19CYP1A2CYP2C9HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423445-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2020-04-01 — — EP disclosed
Send feedback